CymaBay stock pops 7% after launching stock and warrants offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
32,480$
0,03%
Echtzeit-Aktienkurs CymaBay Therapeutics Inc.
Bid:
Ask:
Nachrichten zur CymaBay Therapeutics Inc. Aktie
CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused…
Form 8-K CymaBay Therapeutics, For: Jan 06
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
CymaBay join hands with Kaken to develop, commercialize Seladelpar
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis
Advances strategy to partner seladelpar for PBC outside U.S....…
CymaBay Therapeutics GAAP EPS of -$0.28 beats by $0.02
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. ET Conference call and webcast today at 4:30 p.m. ET...…
CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022
NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on…
Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?
Here is how Akero Therapeutics, Inc. (AKRO) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far…
CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022
NEWARK, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on…